Novo Nordisk may already have one blockbuster obesity drug in its portfolio, but the Danish drugmaker has actively begun searching out others, including through a new partnership announced Thursday.
Novo Nordisk will work with Omega Therapeutics, a startup founded by venture creation firm Flagship Pioneering, to develop a genetic editing treatment for obesity. The pharmaceutical company said Thursday that it has also signed a deal with Flagship-founded startup Cellarity to develop a new medicine for the fatty liver disease MASH, formerly known as NASH.
These are the first two deals announced under a collaboration agreement Flagship and Novo Nordisk struck in 2022.